SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurex Corporation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James F. Worfolk who wrote (359)10/7/1997 11:13:00 PM
From: Jeffers Hughes   of 449
 
No specific information ia available. However, look at the gains of several companies due to the positive data of clinical trial: IMNX, SCIO and MEDI gained about 30% in the day of announcing the news. IMNX was more than doubled in this quarter. HIV was doubled for its positive resutls of two trials. BTIM is another example of doubled price in two weeks after it announced accomplishing the phase III trial (low 30s to high 70s). One comparable example is NSTA that also makes pain-reliever drug. Its price went up to as high as 29 from 10s during the time when FDA approved its drug. Thus, there will be a great potential for NXCO in one or two months when it finishes its phase III trial of the lead drug, SX111.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News